Who
Michael Halstead
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Cybin; President, Intra-Cellular Therapies; Senior V.P., Corp. Development, Warner Chilcott.
In numbers
- Trades disclosed
- 212
- Buys
- 3
- Sells
- 45
- Bought
- $3.0M
- Sold
- $33.5M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 30 Jun 2011
- Last trade
- 21 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 21 Sep 2026 | CybinBiotechnology | SEC FORM 4 Bought | $1.3M100,000 at $13.47 | filing |
| 21 Sep 2026filed 21 Sep 2026 | HELP Helus PharmaBiotechnology | SEC FORM 4 Bought | $1.3M100,000 at $13.47 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —40,472 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —17,916 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —13,133 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —24,478 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —45,454 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —13,134 at $0.00 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —13,134 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code A | —12,240 at $0.00 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —12,240 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapies | SEC FORM 4 Code D | $2.8M21,307 at $132.00 | filing |
| 10 Mar 2025filed 10 Mar 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code M | —7,345 at $0.00 | filing |
| 10 Mar 2025filed 10 Mar 2025 | Intra-Cellular Therapies | SEC FORM 4 Code M | —7,345 | filing |
| 10 Mar 2025filed 10 Mar 2025 | Intra-Cellular Therapies | SEC FORM 4 Code F | $493K3,757 at $131.24 | filing |
| 6 Mar 2025filed 10 Mar 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code M | —13,133 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | Intra-Cellular Therapies | SEC FORM 4 Code M | —13,133 | filing |
| 6 Mar 2025filed 10 Mar 2025 | Intra-Cellular Therapies | SEC FORM 4 Code F | $881K6,718 at $131.19 | filing |
| 1 Mar 2025filed 4 Mar 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code M | —12,239 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | Intra-Cellular Therapies | SEC FORM 4 Code M | —12,239 | filing |
News
Helus Pharma Appoints Dr. Suresh Durgam to Board of DirectorsHELP · recorder.ca · 15 Oct 2026Helus Pharma to Host Investor Presentation on October 21, 2026HELP · simcoereformer.ca · 8 Oct 2026
0 headlines in the last 90 days name Michael Halstead; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.